Role of Dopamine-Based Antidepressants in Treating Depression

Mechanism of Action and Efficacy

Bupropion has been shown to be an effective antidepressant with comparable efficacy to other second-generation antidepressants, making it a valuable option for patients concerned about sexual side effects or those who have not responded to SSRIs, according to the American College of Physicians 1
Clinical trials have demonstrated bupropion's efficacy in treating major depressive disorder (MDD) with response rates comparable to other second-generation antidepressants, as reported by the American College of Physicians 1
The American Psychiatric Association notes that bupropion was shown to be effective as a second-line agent for patients who did not respond to initial SSRI therapy, with approximately 25% of patients achieving remission 2

The American College of Physicians recommends that treatment with bupropion should be monitored regularly beginning within 1-2 weeks of initiation, with modification if there is no adequate response within 6-8 weeks 3
The American College of Physicians also notes that the typical therapeutic dose range is 300-450 mg/day, with careful titration recommended to minimize the risk of adverse effects, and that treatment should be monitored regularly beginning within 1-2 weeks of initiation, with modification if there is no adequate response within 6-8 weeks 4

Bupropion is associated with a lower rate of sexual adverse events compared to SSRIs, making it a preferred option for patients concerned about sexual dysfunction, as noted by the American College of Physicians 3
The National Comprehensive Cancer Network recommends bupropion for smoking cessation, making it particularly useful for depressed patients who also smoke 5

Common side effects of bupropion include insomnia, dry mouth, headache, nausea, dizziness, constipation, and tremor, as reported by the American College of Physicians 4
The National Comprehensive Cancer Network notes that bupropion lowers the seizure threshold, with a 0.1% seizure risk reported in clinical trials, making it contraindicated in patients with a history of seizures 5

The American Gastroenterological Association recommends dose adjustments for patients with moderate to severe renal or hepatic impairment 6
The American Gastroenterological Association also notes that bupropion should be avoided in patients taking monoamine oxidase inhibitors (MAOIs) and used with caution in patients requiring opioid medications due to the potential for reduced analgesic efficacy 6

The American College of Physicians recommends evaluating depression severity, symptom profile, and comorbidities when considering bupropion as a treatment option, and notes that bupropion may be particularly beneficial for patients with depression and comorbid conditions such as ADHD or nicotine dependence 1
The American College of Physicians also recommends continuing treatment for 4-9 months after satisfactory response for first episode; longer for recurrent depression, as noted in the treatment guidelines 7

The American College of Physicians recognizes that augmenting citalopram with bupropion decreases depression severity more than augmentation with buspirone, with lower discontinuation rates due to adverse events 8

The American College of Physicians recognizes that augmenting SNRI therapy with bupropion achieves response in 56-80% of patients who failed initial antidepressant treatment, providing a significant clinical benefit 8

The American College of Physicians recommends continuing combination treatment for 4-9 months after satisfactory response for first episode, and longer duration for patients with 2 or more depressive episodes 9